NCT04577404: A reported trial by Tanabe Pharma America, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04577404 |
|---|---|
| Title | A Phase 3, Multi-center, Open-label, Safety Extension Study of Oral Edaravone Administered Over 96 Weeks in Subjects With Amyotrophic Lateral Sclerosis (ALS) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 29, 2020 |
| Completion date | Aug. 9, 2023 |
| Required reporting date | Aug. 8, 2024, midnight |
| Actual reporting date | July 29, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |